Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy.
Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy.
复制标题
DOI：
10.1016/j.semcancer.2017.11.019
复制
发表时间：
2018-10
影响因子：
14.5
通讯作者：
Li QK
中科院分区：
文献类型：
--
作者：
Osmani L;Askin F;Gabrielson E;Li QK
最近来自临床肺癌基因组计划的大规模基因组研究发现，在非小细胞肺癌(NSCLC)的不同亚型中存在不同的驱动基因突变。这些发现不仅使肺癌患者的靶向治疗取得了显著进展，也为非小细胞肺癌的亚型提供了基础知识。最近，免疫治疗的进步和临床应用加强了对非小细胞肺癌准确亚型的需求。2015年，世界卫生组织(WHO)和国际肺癌研究协会(IASLC)更新了肺癌细分分类指南。这些指南强调：(1)非小细胞肺癌的分类，(2)肿瘤分子特征在靶向治疗中的关键作用，(3)使用小活检标本对非小细胞肺癌进行分类的独特术语，以及(4)IHC生物标记物在肺癌准确诊断和分类中的应用。该指南对肿瘤学实践和患者护理有重大的预后影响。在本文中，我们总结了目前WHO肺癌分类指南，讨论了靶向治疗和免疫治疗的进展，讨论了免疫标记物在非小细胞肺癌分类中的作用和局限性，并展望了该领域的未来。
Recent large scale genomic studies from the Clinical Lung Cancer Genome Project have identified different driver gene mutations in the subtypes of non-small cell lung carcinoma (NSCLC). These findings not only lead to remarkable progress in targeted therapies for lung cancer patients, but also provide fundamental knowledge for the subclassification of NSCLC. More recently, the advancement and clinical application of immunotherapy have reinforced the need for the accurate subclassification of NSCLC. In 2015, the World Health Organization (WHO) and the International Association for the Study of Lung Cancer (IASLC) updated their guidelines for the subclassification of lung cancers. These guidelines emphasize: (1) the subclassification of NSCLC, (2) the critical role of molecular characterization of tumors for targeted therapy, (3) the unique terminology for subclassifying NSCLC using small biopsy specimens, and (4) the utility of IHC biomarkers in the accurate diagnosis and subclassification of lung cancer. The guidelines have significant prognostic impact on oncologic practice and patient care. In this review, we summarize the current WHO guidelines for the classification of lung cancer, discuss advancements of targeted therapy and immunotherapy, and address the utility and limitation of immunomarkers in the subclassification of NSCLC, as well as the prospective future of the field.
登录
查看更多内容
影响因子：
3.4
作者：
Fatima, Nazneen;Cohen, Cynthia;Siddiqui, Momin T.
通讯作者：
Siddiqui, Momin T.
影响因子：
10.6
作者：
Gurda GT;Zhang L;Wang Y;Chen L;Geddes S;Cho WC;Askin F;Gabrielson E;Li QK
通讯作者：
Li QK
影响因子：
28.4
作者：
Rimm DL;Han G;Taube JM;Yi ES;Bridge JA;Flieder DB;Homer R;West WW;Wu H;Roden AC;Fujimoto J;Yu H;Anders R;Kowalewski A;Rivard C;Rehman J;Batenchuk C;Burns V;Hirsch FR;Wistuba II
通讯作者：
Wistuba II
影响因子：
7.5
作者：
Gniadek, Thomas J.;Li, Qing Kay;Gabrielson, Edward
通讯作者：
Gabrielson, Edward
影响因子：
20.4
作者：
Hirsch, Fred R.;McElhinny, Abigail;Kerr, Keith M.
通讯作者：
Kerr, Keith M.